

## Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma

Michael A. Badruddoja<sup>1,2</sup> · Marjorie Pazzi<sup>1</sup> · Abhay Sanan<sup>1</sup> · Kurt Schroeder<sup>1</sup> · Kevin Kuzma<sup>3</sup> · Thomas Norton<sup>1</sup> · Thomas Scully<sup>1,4</sup>  · Daruka Mahadevan<sup>5</sup>  · Michael Malek Ahmadi<sup>1,3</sup> 

Published online: 16 October 2017  
© Springer-Verlag GmbH Germany 2017

**Correction to: Cancer Chemother Pharmacol**  
**(2017) 80:715–721**  
**DOI [10.1007/s00280-017-3405-7](https://doi.org/10.1007/s00280-017-3405-7)**

The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading.

The second sentence of the “Introduction” section should read as:

A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].

---

The online version of the original article can be found under doi:[10.1007/s00280-017-3405-7](https://doi.org/10.1007/s00280-017-3405-7).

---

✉ Michael A. Badruddoja  
badru001@neurotucson.com

✉ Daruka Mahadevan  
dmahadevan@uacc.arizona.edu

<sup>1</sup> Center for Neurosciences, 2450 E River Rd, Tucson, AZ 85718, USA

<sup>2</sup> Department of Radiation Oncology, Banner University Medical Center, 1501 N. Campbell Avenue, Tucson, AZ 85724, USA

<sup>3</sup> Genentech, Inc., DNA Way, South San Francisco, CA 94080, USA

<sup>4</sup> Northwest Neurospecialists, 5860 N. La Cholla Blvd. Suite 100, Tucson, AZ 85741, USA

<sup>5</sup> University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, AZ 85724, USA